Analyst Group: Equity Research Report on STENOCARE - Transforms to a Profitable Growth Company
STENOCARE A/S (“STENOCARE” or the “Company”) is a medical cannabis trading company with products approved and available for patients in six countries. The Company has recently launched a premium product, Astrum 10-10, which Analyst Group sees as an important growth driver in the coming years, as it distinguishes STENOCARE from competitors, providing improved, uniform and faster uptake in the blood. The product became available to patients in three countries during Q1-25, Germany, Australia, and Norway. With estimated net sales of DKK 17.2m by 2027, an applied P/S multiple of 3x and a discount rate of 14%, a potential present value per share of DKK 1.01 (0.89) is derived in a Base scenario.
Read the equity research report here
About Analyst Group: One of Sweden's leading analysis houses with a focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of an equity research report on STENOCARE. Readers may assume that Analyst Group has received compensation for making the equity research report. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation, or anything else that could be considered a subjective assessment.
